{
    "ticker": "INBS",
    "name": "Inhibikase Therapeutics, Inc.",
    "description": "Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, particularly Parkinson's disease. Founded in 2015, Inhibikase is dedicated to advancing treatments that target the underlying pathophysiology of these disorders rather than merely alleviating symptoms. The company's lead product candidate, IkT-148009, is an oral small molecule designed to inhibit kinases involved in the pathology of Parkinson's disease and represents a significant advancement in the treatment landscape. Inhibikase is driven by a mission to improve the quality of life for patients suffering from neurodegenerative conditions through innovative science and rigorous clinical development. The company is committed to bringing new therapies to market that can modify disease progression and restore function, thereby addressing the unmet needs of patients and their families. With a strong pipeline of candidates and strategic partnerships in research and development, Inhibikase is positioned to make a meaningful impact in the field of neurodegeneration.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Atlanta, Georgia, USA",
    "founded": "2015",
    "website": "https://www.inhibikase.com",
    "ceo": "Matthew C. McCluskey",
    "social_media": {
        "twitter": "https://twitter.com/Inhibikase",
        "linkedin": "https://www.linkedin.com/company/inhibikase-therapeutics/"
    },
    "investor_relations": "https://www.inhibikase.com/investor-relations",
    "key_executives": [
        {
            "name": "Matthew C. McCluskey",
            "position": "CEO"
        },
        {
            "name": "Dr. John D. Quinton",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IkT-148009"
            ]
        }
    ],
    "seo": {
        "meta_title": "Inhibikase Therapeutics, Inc. | Innovating Neurodegenerative Disease Treatments",
        "meta_description": "Inhibikase Therapeutics, Inc. is focused on developing innovative therapies for neurodegenerative diseases, targeting the underlying causes of conditions like Parkinson's disease.",
        "keywords": [
            "Inhibikase",
            "Neurodegenerative Diseases",
            "Parkinson's Disease",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Inhibikase Therapeutics known for?",
            "answer": "Inhibikase Therapeutics is known for developing novel therapeutics for neurodegenerative diseases, particularly Parkinson's disease."
        },
        {
            "question": "Who is the CEO of Inhibikase Therapeutics?",
            "answer": "Matthew C. McCluskey is the CEO of Inhibikase Therapeutics, Inc."
        },
        {
            "question": "Where is Inhibikase headquartered?",
            "answer": "Inhibikase is headquartered in Atlanta, Georgia, USA."
        },
        {
            "question": "What is Inhibikase's lead product candidate?",
            "answer": "Inhibikase's lead product candidate is IkT-148009, designed to target kinases involved in Parkinson's disease pathology."
        },
        {
            "question": "When was Inhibikase founded?",
            "answer": "Inhibikase was founded in 2015."
        }
    ],
    "competitors": [
        "ACAD",
        "PTCT",
        "NERV",
        "AXSM"
    ],
    "related_stocks": [
        "BIIB",
        "AMGN",
        "VRTX",
        "GILD"
    ]
}